GNPAT

Across TCGA pan-cancer cohorts, GNPAT mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GNPAT data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GNPAT mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GNPAT expression acts as an unfavorable survival marker.

HNSC, LUAD, and CCRCC are the cancer types where GNPAT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	III,IV	0.188	0.895	.003	63	view →
LUAD	DFS	Tertile	All	0.491	0.837	<.001	46	view →
CCRCC	DFS	Quartile	All	0.620	0.871	.006	27	view →
LSCC	DFS	Median	All	0.594	0.802	.007	9	view →
PDAC	OS	Median	IV	0.381	0.951	.006	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GNPAT–HNSC (DFS)

Open the HNSC breakdown →